Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2775)	7/3/2012 10:36:37 AM
From: tuck	1 Recommendation Respond to of 3027

M402 => should we be watching Curis' GDC-0449 in pancreatic cancer? In this poster on M402, it is suggested that its MOA for reduction of primary tumor weight and metastases is through sonic hedgehog. Note the trial design for the first in human study -- which dosed its first patient this past week -- is also given. Data from part one will be out in 1H13, and it will simply be dose ranging & safety. Given the design, I'd guess that part two, which will have some efficacy data, will be out around mid to late 2014. momentapharma.com Folks talk similar talk for GDC-0449, which is also an inhibitor of SHH, and which is being trialed by several entities in pancreatic cancer, having been recently approved for advanced BCC. Data readouts should be coming steadily in advance of data for M402. seekingalpha.com I would guess the tox profiles are somewhat different for these two drugs. I don't think we know much yet about M402 in this regard, except to look for how well the anticoagulant properties have been engineered out. GDC-0449's SE profile (spasms, dysgeusia, alopecia, weight loss, joint pain, GI effects of various sorts, etc), can be seen here: gene.com Cheers, Tuck